ClinicalTrials.gg
Active, not recruitingNCT02767505BESTUpdated Feb 9, 2024

Bypass Equipoise Sleeve Trial (BEST)

An interventional study of gastric bypass and Sleeve gastrectomy in Severe Obesity, sponsored by Göteborg University. Active, not recruiting at 21 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by Göteborg University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,752
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Obesity, Morbid with a site in Sweden — 3 open to participants now, 5 under way, none of them phase 3. Obesity, Morbid · Sweden.

Started
2015
with 1 other
No phase
8 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
4 of 16
Göteborg University

Among the 16 studies in Obesity, Morbid with a site in Sweden, this one is one of 2 that started in 2015, is one of 8 with no phase, and was the 10th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

3 of the 16 studies in Obesity, Morbid with a site in Sweden are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Obesity, Morbid with a site in Sweden, or all of them as a file.
02

Study summary

This is nationwide registry-based randomised clinical multicenter trial in which patients will be randomised to gastric bypass (RYGB) or sleeve gastrectomy (SG). The co-primary endpoint are weight control over 5 years and the amount of severe adverse events. Additionally the investigators have predefined a number of secondary endpoints, and the trial has a sufficient number of patients to allow comparisons across subgroups.

Read the detailed description

Follow-up of the patients will use the routines respectively for regular follow-up on the Scandinavian Obesity Surgery Registry (SOReg) after 6v, 1 year, 2 years, and after 5 years.

In order to evaluate if SG has advantages compared to the previous standard, the investigators want to examine whether SG operations are equivalent (non-inferiority) for weight loss and weight stability five years after surgery in comparison to RYGB, and if SG is associated with fewer long-term complications (superiority). The primary outcome measure emanates from assessment of long term weight management and the frequency of serious complications.

The unforeseen global Covid-19 pandemic resulted in that almost all elective benign surgery in Scandinavia was cancelled from March 2020. Thus, the pandemic had severe consequences on the recruitment to the BEST trial during 2020-2021.

During autumn of 2021 the BEST steering committee decided to perform an additional analysis of the power for primary endpoints.

Additional information (Courcoulas et al, JAMA Surg 2020 March; Howard et al, JAMA Surg 2021 Dec) revealed that the risk of any of the predefined substantial adverse events after bariatric surgery is higher than previously anticipated in the revised power calculation, i.e. >25% instead of 13%. These figures were confirmed in an analysis of real-world data from the bariatric national quality register SOReg in Sweden which registered all patients undergoing sleeve or bypass in Sweden since 2007.

An independent statistician performed the analysis based on information above, but also on 2-year data in BEST. In conclusion, it was stated:

Two post hoc power analyses were conducted based on the data from February 2022:

  1. Weight reduction. In the protocol the following is stated "This sample size will also have >95% power to evaluate non-inferiority of 5% weight loss difference over 5 years between the two groups, assuming 15 kg standard deviation in weight loss over follow-up with two-sided 2.5% significance level.". The post hoc power calculation is based on the two-year follow up data where an average weight loss for all patients (both groups, N=1031) of 29.3 kg was attained with a Sd=21.6. Given a loss to follow up of 20% from 2 year follow up to the 5-year follow up the sample size is assumed to be (1031*0.80)/2=413 patients per group. With a non-inferiority level of 5 kg weight loss the power is found to be 90% if n=393 per group, and 95% if n=486 per group (https://www.sealedenvelope.com/power/continuous-noninferior/).
  2. Substantial adverse events. This post hoc power calculation is for a superiority test where the rate is assumed to be 25% for the gastric bypass at 5 years and sleeve would have a 35% lower level, i e 25%*0.65=16.25%. Given a sample of n=413 per group the post hoc power will then be 87.5%.

Taking information above into account and in the interest of not prolonging inclusion period unnecessarily the trial steering committee took a decision to stop inclusion in BEST during spring 2022 (final date 31st of March). At termination of inclusion the number of participants that had been included and operated in BEST were 1752. The trial Data Safety and Monitoring Committee reviewed and supported the decision before termination of recruitment to the BEST trial.

03

Conditions studied

  • Severe Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 35-50 kg/m2
  • Ability to understand and decide on the merits of the study participation
  • Accepted for bariatric surgery
  • Must understand the information, and be able to make a decisions about participation in the study

Exclusion criteria

Exclusion Criteria:

  • Previous bariatric surgery, anti reflux surgery or other gastric surgery
  • Moderate to severe reflux disease, Barretts oesophagus or known hiatus hernia >4 cm
  • Unstable mental illness or other known to bariatric surgery.
  • Planned significant surgery at the same time
  • Inflammatory bowel disease
  • ongoing drug or substance abuse
  • not appropriate to randomise the patient, according to surgeon
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,752 participants (actual)

Study arms

  • Experimental
    Sleeve gastrectomy

    Laparoscopic sleeve gastrectomy

    Other: Sleeve gastrectomy

  • Active comparator
    Gastric bypass

    Laparoscopic Roux-en-Y gastric bypass

    Other: gastric bypass

Interventions

  • Othergastric bypass

    Type of surgery: gastric bypass

  • OtherSleeve gastrectomy

    Typ of surgery: sleeve gastrectomy

06

What researchers measure

Primary outcomes

  1. Weight loss

    Non-inferiority for SG is defined as \< 5% weight difference

    Time frame: 5 years

  2. Serious adverse events

    Superiority for SG is having 35% less serious (substantial) adverse events compared to RYGB

    Time frame: 5 years

Secondary outcomes

  1. Adverse events

    General description of patterns of all adverse events

    Time frame: 1, 2, 5 and 10 years

  2. Weight loss

    Between baseline and 1 and 2 years

    Time frame: Baseline, 1, 2, 5 and 10 years

  3. Number of patients with arterial cardiovascular events

    Composite of myocardial infarction+ stroke+ other occlusive arterial condition

    Time frame: Baseline, 1, 2, 5 and 10 years

  4. Number of patients with venous event

    Composite of Deep vein thrombosis+ Pulmonary emboli+ other venous event

    Time frame: Baseline, 1, 2, 5 and 10 years

  5. Number of patients with diabetes requiring drug treatment

    Development of diabetes measured as numbers of patients having a diabetes diagnosis and oral medication and injection therapy

    Time frame: Baseline, 1, 2, 5 and 10 years

  6. Number of patients with a psychiatric morbidity

    Number of patients with a psychiatric morbidity

    Time frame: Baseline, 1, 2, 5 and 10 years

  7. Number of patients with hypertension treatment

    Number of patients with hypertension treatment (any type of Medical treatment)

    Time frame: Baseline, 1, 2, 5 and 10 years

  8. Number of patients diagnosed with a malignancy

    Number of patients diagnosed with a malignancy

    Time frame: Baseline, 1, 2, 5 and 10 years

  9. Number of patients with dyslipidemia treatment

    Number of patients with diagnosis of dyslipidemia and on oral lipid lowering treatment

    Time frame: Baseline, 1, 2, 5 and 10 years

  10. Weight in men and women

    Analyses of the primary outcome weight in men and women

    Time frame: Baseline, 1, 2, 5 and 10 years

  11. serious adverse events in men and women

    Analyses of the primary outcome serious adverse events in men and women

    Time frame: Baseline, 1, 2, 5 and 10 years

  12. Weight in patients with BMI >43 vs <43 kg/m2.

    Analyses of the primary outcome weight in patients with BMI \>43 vs \<43 kg/m2.

    Time frame: Baseline, 1, 2, 5 and 10 years

  13. Serious adverse events in patients with BMI >43 vs <43 kg/m2

    Analyses of the primary outcome serious adverse events in patients with BMI \>43 vs \<43 kg/m2.

    Time frame: Baseline, 1, 2, 5 and 10 years

  14. Weight in patients aged 18-25 y, 25-50 y, or >50 y

    Analyses of the primary outcome weight in patients aged 18-25 y, 25-50 y, or \>50 y

    Time frame: Baseline, 1, 2, 5 and 10 years

  15. Serious adverse events in patients aged 18-25 y, 25-50 y, or >50 y

    Analyses of the primary outcome serious adverse events in patients aged 18-25 y, 25-50 y, or \>50 y

    Time frame: Baseline, 1, 2, 5 and 10 years

  16. Mineral nutritional status

    Serum concentrations of iron depots, zinc, magnesium, selenium and copper

    Time frame: Baseline, 1, 2, 5 and 10 years

  17. Vitamin nutritional status

    Serum concentrations of vitamins (Vitamin B12, Vitamin D, Vitamin A, thiamin)

    Time frame: Baseline, 1, 2, 5 and 10 years

  18. Serum concentrations of albumin

    Serum concentrations of Albumin

    Time frame: Baseline, 1, 2, 5 and 10 years

  19. Changes in quality of Life assessed with EQ-5D

    Assessed with EQ-5D

    Time frame: Baseline, 1, 2, 5 and 10 years

  20. Changes in quality of Life assessed with Obesity Problems (OP)

    Assessed with Obesity Problems (OP)

    Time frame: Baseline, 1, 2, 5 and 10 years

  21. Changes in quality of Life assessed with Short Form-36

    Assessed with SF-36

    Time frame: Baseline, 1, 2, 5 and 10 years

  22. Alcohol consumption

    Assessed by AUDIT

    Time frame: 1, 2, 5 and 10 years

  23. Gastro-esophageal reflux disease

    Gastro-esophageal reflux disease is defined as present/ not present in at least one of following modalities: Questionnaire DeMeester score, 24h pH manometry and/or gastroscopy

    Time frame: 1, 2, 5 and 10 years

  24. Fracture incidence

    From clinical data and national registry

    Time frame: 2, 5 and 10 years

  25. Bone density and body composition

    Dual energy X-ray Absorptiometry (DEXA) in at least a subgroup of 500+500

    Time frame: 10 years

  26. Mortality and cause of death

    National Cause of Death registry

    Time frame: 5, 10, 20 and 30 years

  27. Health care consumption, In hospital registry

    Data from In hospital registry (Days in hospital)

    Time frame: 5, 10, 20 and 30 years

  28. Health care consumption,

    Data from Outpatient registry ( number of visits)

    Time frame: 5, 10, 20 and 30 years

  29. Health care consumption

    National drug registry (type of drug)

    Time frame: 5, 10, 20 and 30 years

  30. Development of co-morbidities from national registry data

    National stroke registry, National Cardiac registry, National Diabetes Registry, Cancer registry

    Time frame: 5, 10, 20, 30 years

  31. Formal cost effective analysis

    Cost per quality-adjusted life-year and life-year)

    Time frame: 5, 10 and 20 years

  32. Dietary intake

    Questionnaire regarding food intake (E14x)

    Time frame: 1 and 10 years

  33. Eating patterns

    Three Factor Eating Questionnaire (TFEQ)

    Time frame: 1 and 10 years

  34. Gastro-intestinal side effects

    Questionnaire: Gastro-intestinal Symptom Rating Score (GSRS)

    Time frame: 1 and 10 years

  35. Dumping symptoms

    Questionnaire: Dumping Symptom Rating Score (DSRS)

    Time frame: 1 and 10 years

  36. Adverse events

    Clinical data combined with national registry data

    Time frame: 30 days postop, 1, 2, 5 and 10 years

  37. Peri-operative outcome, Complications

    Complications; Surgical (minor/major) and medical

    Time frame: Up to 30 days postop

  38. Peri-operative outcome, surgical time

    surgical time (min)

    Time frame: Up to 30 days postop

  39. Peri-operative outcome, sick leave

    sick leave (days)

    Time frame: Up to 30 days postop

  40. Peri-operative outcome, length of stay

    length of stay (days)

    Time frame: Up to 30 days postop

07

Study locations

21 sites
08

References and documents

Publications

  • Hedberg S, Olbers T, Peltonen M, Osterberg J, Wiren M, Ottosson J, Thorell A; BEST study group. BEST: Bypass equipoise sleeve trial; rationale and design of a randomized, registry-based, multicenter trial comparing Roux-en-Y gastric bypass with sleeve gastrectomy. Contemp Clin Trials. 2019 Sep;84:105809. doi: 10.1016/j.cct.2019.07.001. Epub 2019 Jul 4. PubMed 31279778 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Dec 2026 and a completion of Dec 2031. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2015
First posted
May 10, 2016
Start
Sep 2015
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2031
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02767505
Collaborators
Ersta Hospital, Sweden, Region Örebro County, Kalmar County Hospital, Lindesbergs Hospital, Danderyd Hospital, Skaraborg Hospital, Sodertalje Hospital, Östra Hospital, Mora Hospital, Torsby Hospital, Stockholm South General Hospital, Gävle Hospital, Uppsala University Hospital, Lycksele Hospital, Falu Hospital, Vrinnevi Hospital, Norrköping, Capio S:t Görans Hospital, Ljungby Hospital, Sykehuset i Vestfold HF, Gjövik Hospital, Norway, GB Obesitas Skane
Responsible party
Sponsor
First posted
May 10, 2016
Start date
Sep 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2031 (estimated)
Last update
Feb 9, 2024

Study contacts

Torsten Olbers, MD, PhD
principal investigator · Linköping University, Dept of BKV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion